This content is machine translated Sponsored Content: Advanced therapy for the 1st line of treatment New approval of SKYRIZI® (risankizumab) for ulcerative colitis [1] Ulcerative colitis (UC) can lead to progressive intestinal damage and massive restrictions in the daily lives of those affected [2]. With the approval of SKYRIZI® (risankizumab), a new first-line therapy...…
View Post 5 min This content is machine translated Sponsored Content: Pulmonary hypertension Also consider pulmonary hypertension in case of unexplained shortness of breath! Unexplained breathlessness is a frequent and challenging problem in the daily practice of general practitioners, pulmonologists and cardiologists. One possible underlying clinical picture is pulmonary hypertension (PH), which is often...…
View Post 8 min This content is machine translated SGDV Congress 2024: Atopic dermatitis and psoriasis Happy patient, happy doctor? At the AbbVie Symposium as part of the SGDV Congress 2024, Prof. Dr. Curdin Conrad (CHUV Lausanne) and Prof. Dr. Kilian Eyerich (University of Freiburg, Germany) discussed the concept of…
View Post 1 min This content is machine translated Online training Swiss Oncology in Motion Module Prostate Cancer Treatment options for prostate cancer have evolved rapidly over the past two years, with advances across the spectrum of disease stages. Prof. em. Dr. med Richard Herrmann speaks in the… CME-Test
View Post 1 min This content is machine translated Swiss Oncology in Motion SOiM Urothelial carcinoma – Update Oncology is constantly changing, with additional diagnostic procedures, new surgical methods and innovative therapeutic concepts being developed. For this reason, the treatment guidelines are also continuously revised. Therefore, this module… CME-Test
View Post 7 min This content is machine translated Sponsored Content: Rheumatoid arthritis Switching to upadacitinib as an advantageous alternative to TNFi cycling [1] The treatment of rheumatoid arthritis (RA) has made significant progress in recent years, but therapy remains a challenge for many patients: up to 60 % of those affected either do…
View Post 4 min This content is machine translated Sponsored Content: Crohn's disease Biomarkers underline superiority of risankizumab compared to ustekinumab in Crohn’s disease [1] In the SEQUENCE study, risankizumab was compared with ustekinumab for the treatment of Crohn’s disease (CD) in patients who had failed anti-TNF therapies. Biomarkers such as fecal calprotectin (FC) and…
View Post 7 min This content is machine translated Sponsored Content: Inflammatory skin diseases “New horizons” in the treatment of inflammatory skin diseases The field of inflammatory skin diseases is constantly evolving. Updates on current standard treatments, innovative therapy options and artificial intelligence were presented at two accredited live webinars entitled “New Horizons…
View Post 8 min This content is machine translated Sponsored Content Personalized therapy for recurrent urinary tract infections Urinary tract infections are the most common bacterial infection in women and pose a major challenge both in everyday practice and in the clinic. Women have a significantly higher risk…
View Post 5 min This content is machine translated Sponsored Content: United European Gastroenterology Week (UEGW) 2023 Risankizumab demonstrates superiority compared to ustekinumab in Crohn’s disease [1] Data from the current SEQUENCE study was presented at the United European Gastroenterology Week (UEGW), which took place from October 14 to 17, 2023, and has since been published [1,2].…
View Post 6 min This content is machine translated 11th Swiss IBD Roadshow “Curing mucosa is our major goal” The meanwhile 11th Swiss IBD Roadshow (10. – 12. June 2024) took place this year under the title “ADVANCED THERAPIES IN IBD – TOWARDS A NEW SEQUENCE”. Between his lectures…
